Century India Opportunity Fund Buys 16 Lakh Shares of This Pharma Stock At Rs 41.97

On Friday, Century India Opportunity Fund pc made a significant investment to acquire the majority controlling stake in Sudarshan Pharma Industries Ltd by buying 16,00,000 shares at the rate of 41.97 rupees per share through an open market. The total amount spent is equivalent to 6.71 crore rupees and it represents the confidence investors have on the growth of this particular company.

Sudarshan Pharma was able to gain 1.20% at the end of the trading session culminating in a pricing circuit of 42.50 rupees cutting short the previous trading close price of 42 rupees. There has been extreme share volatility for the company with the highest price being 46 rupees and the lowest price price being 5.82 rupees in the last 52 weeks. This increase from the low use price over a period of time managed to yield a profit of over 630 percent returns.

Sudarshan Pharma operates with a market cap of 992 crore rupees and it has been able to realize growth in net profits and increase with a compound annual growth rate of 37% over the last 5 years. As a result, the company has shifted to more investors because of their strong growth of the company which is able to deliver consistent returns.
The company was able to carry out share splits in order to increase the number of shareowners in the company and lower share owners in the company. All equity shares with a nominal value of 10 rupees were subdivided into ten 1 rupee shares and opened up new doors for investment institutions or individuals.

On top of that, Everybody Nordikas had spread its wings and moved into developing subsidiaries through acquisitions that were relevant to its business.

The company took over Ishwari Healthcare Private Limited by acquiring 2, 09,100 equity shares which represent 51% of the total shares. Ishwari Healthcare specializes in manufacturing and distribution of medical and surgical instruments along with R & D and it has now become a subsidiary of the company. This acquisition is in line with what Sudarshan Pharma intends to do, which is expand its range of offerings in the healthcare sector.

To further augment its footprint in the market, Sudarshan Pharma has incorporated another subsidiary called Sudarshan Maven Pharma Private Limited. The company took up 70% shares of Sudarshan Maven. This entity manufactures pharmaceutical products such as active pharmaceutical ingredients, pharmaceutical intermediates, antibiotics and Ayurveda supplements. With such expansions, Sudarshan Pharma is in a good position to take advantage of the increasing demand in the conventional and unconventional healthcare fields.

Sudarshan Pharma Industries Limited is a Mumbai-based company which has been in operation since 2008 and provides generic pharmaceutical formulations on a contractual basis. The company is also involved in many tasks including but not limited to specialty Chemicals, Intermediates, APIs and pharmaceutical generics services for institutions and healthcare institutions in India.

Additionally, SPIL has ventured into manufacturing branded pharmaceutical products under its Vimac Healthcare division, having registered 56 out of the 96 products under trademark "R". In addition, the company provides Contract Manufacturing Services and works with top Indian pharmaceutical companies and institutional clients.

Sudarshan Pharma has earned integrity and leadership in the chemical and pharmaceutical industry due to its unique business model, acquisitions and most especially its diversification strategies.

Amid increasing investor interest and expansive growth, the company is well positioned on the financial and market success scale.

The recent investment made by Century India Opportunity Fund reinforces the profile of Sudarshan Pharma as a company with high growth prospects.